Management of Hyoscyamine-Induced Bradycardia
Discontinue hyoscyamine immediately and administer atropine 0.5-1 mg IV if the patient is symptomatic or hemodynamically unstable. 1
Understanding the Problem
Hyoscyamine is an anticholinergic/antimuscarinic agent, so bradycardia from hyoscyamine is paradoxical and extremely rare. The FDA label confirms hyoscyamine acts on muscarinic receptors in the sinoatrial and atrioventricular nodes 2, typically increasing heart rate by blocking parasympathetic effects. However, if bradycardia occurs in a patient taking hyoscyamine, consider:
- Drug interaction or overdose context - The patient may have concurrent medications or conditions causing bradycardia
- Underlying conduction disease - Pre-existing sinus node dysfunction (SND) or AV block unmasked by other factors
- Misattribution - The bradycardia may be unrelated to hyoscyamine
Immediate Management Algorithm
Step 1: Assess Hemodynamic Stability
Determine if the patient has any of the following:
- Ischemic chest pain
- Dyspnea or respiratory distress
- Syncope or altered mental status
- Systolic blood pressure <90 mmHg 3
Step 2: If Symptomatic or Unstable
Administer atropine 0.5-1 mg IV (may repeat every 3-5 minutes to maximum 3 mg total) 1. This is the Class IIa recommendation for symptomatic bradycardia from the 2018 ACC/AHA/HRS guidelines.
- Atropine blocks muscarinic receptors, increases sinus node automaticity, and facilitates sinoatrial conduction 1
- Caution: Doses <0.5 mg may paradoxically worsen bradycardia 1
- Response typically occurs within 1 minute of administration 3
Step 3: If Atropine Fails or Patient Deteriorates
Escalate to catecholamine infusions 1:
- Dopamine: 5-20 mcg/kg/min IV (start at 5 mcg/kg/min, increase by 5 mcg/kg/min every 2 minutes)
- Epinephrine: 2-10 mcg/min IV titrated to effect
- Isoproterenol: 1-20 mcg/min infusion (use cautiously if coronary ischemia suspected)
Step 4: Consider Temporary Pacing
If bradycardia remains refractory to medical therapy and hemodynamically unstable, temporary transvenous pacing is reasonable (Class IIa) 1. Transcutaneous pacing may be considered as a bridge (Class IIb) 1.
Critical Considerations
Rule Out Synergistic Causes
Bradycardia in the setting of hyoscyamine use may reflect:
- Hyperkalemia - Check electrolytes immediately 4
- Beta-blocker or calcium channel blocker toxicity - Requires specific antidotes (glucagon, calcium, high-dose insulin) 1
- Renal failure - Can cause drug accumulation and hyperkalemia creating synergistic bradycardia 4
- Cholinesterase inhibitor use - If patient has myasthenia gravis on pyridostigmine, hyoscyamine is actually used to prevent bradycardia 5, so this scenario would be unusual
Important Pitfalls
- Do not use atropine in heart transplant patients without evidence of autonomic reinnervation (Class III: Harm) 1
- Avoid low-dose atropine (<0.5 mg) as it may worsen bradycardia through central vagal effects 1, 6
- Be prepared for paradoxical worsening with atropine if the patient has infranodal (His-Purkinje) block rather than nodal-level block 6
- Temporary transvenous pacing increases infection risk if permanent pacemaker ultimately needed 1
When to Consider Permanent Pacing
If bradycardia persists after discontinuing hyoscyamine and reversible causes are excluded, the patient may have underlying SND or conduction disease requiring permanent pacemaker evaluation per standard guidelines 1, 7.
Medication Discontinuation
Stop hyoscyamine immediately - it has a half-life of 2-3.5 hours and is mostly excreted unchanged in urine within 12 hours 2. Clinical improvement should occur within hours if hyoscyamine was truly causative.